Simplify Asset Management Inc. trimmed its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 33.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,611 shares of the company's stock after selling 808 shares during the quarter. Simplify Asset Management Inc.'s holdings in argenx were worth $991,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of ARGX. Whipplewood Advisors LLC acquired a new stake in argenx in the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC increased its holdings in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after acquiring an additional 48 shares in the last quarter. Jones Financial Companies Lllp grew its position in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after purchasing an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of argenx by 78.6% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock worth $46,000 after buying an additional 33 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its stake in argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after acquiring an additional 21 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.
argenx Stock Down 0.4 %
Shares of NASDAQ ARGX traded down $2.43 during trading on Tuesday, hitting $605.52. The company had a trading volume of 161,825 shares, compared to its average volume of 282,872. The firm has a market capitalization of $36.79 billion, a price-to-earnings ratio of -688.09 and a beta of 0.59. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21. The stock has a fifty day simple moving average of $633.44 and a two-hundred day simple moving average of $600.67.
argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, analysts anticipate that argenx SE will post 3.13 earnings per share for the current year.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the company. JMP Securities increased their price objective on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Piper Sandler lifted their price objective on shares of argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research note on Tuesday, January 7th. William Blair reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. Citigroup reissued an "outperform" rating on shares of argenx in a report on Friday, February 28th. Finally, Robert W. Baird upped their price target on shares of argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a report on Tuesday, March 4th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, argenx currently has a consensus rating of "Moderate Buy" and a consensus target price of $687.00.
Read Our Latest Stock Report on ARGX
About argenx
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Articles
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
